Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial

Mechanisms of diabetes mellitus-induced bone fragility

(2016) Nicola Napoli et al.   Nature Reviews Endocrinology

Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

(2015) Nagesha Guthalu Kondegowda et al.   Cell Metabolism

A Single 60 mg Dose of Denosumab Might Improve Hepatic Insulin Sensitivity in Postmenopausal Nondiabetic Severe Osteoporotic Women

(2015) Elena Passeri et al.   International Journal of Endocrinology

Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial

(2014) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differing effects of denosumab and alendronate on cortical and trabecular bone

(2013) Roger M. Zebaze et al.   BONE

Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials

(2013) Ann V Schwartz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pathogenesis of Prediabetes: Role of the Liver in Isolated Fasting Hyperglycemia and Combined Fasting and Postprandial Hyperglycemia

(2013) Rita Basu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus

(2013) Stefan Kiechl et al.   NATURE MEDICINE

Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study)

(2011) Anne L. Schafer et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Antiresorptive Effects of a Single Dose of Zoledronate Persist for Two Years: A Randomized, Placebo-Controlled Trial in Osteopenic Postmenopausal Women

(2008) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM